SGLT2 Inhibitors and Continuation of Renin Angiotensin Blockade
0:00
21:23
Dr. Briggs and Brendon Neuen discuss his paper in the December issue of JASN. This article on the CREDENCE and EMPA-CKD clinical trials shows that SGLT2 inhibitors allow more consistent use of RAS blockade in patients with declining renal function.
Weitere Episoden von „Journal of the American Society of Nephrology (JASN)“
Verpasse keine Episode von “Journal of the American Society of Nephrology (JASN)” und abonniere ihn in der kostenlosen GetPodcast App.